Cargando…

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma

Detalles Bibliográficos
Autores principales:	Guo, Yelei, Tong, Chuan, Su, Liping, Zhang, Wenying, Jia, Hejin, Liu, Yang, Yang, Qingming, Wu, Zhiqiang, Wang, Yao, Han, Weidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043938/ https://www.ncbi.nlm.nih.gov/pubmed/35008103 http://dx.doi.org/10.1182/bloodadvances.2021006232

Ejemplares similares

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
por: Jia, Hejin, et al.
Publicado: (2019)

Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
por: Zhang, Yajing, et al.
Publicado: (2021)

Characteristics of premanufacture CD8(+) T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma
por: Wang, Yao, et al.
Publicado: (2023)

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
por: Dimitri, Alexander, et al.
Publicado: (2022)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
por: Meier, Jeremy A., et al.
Publicado: (2022)

Universal theranostic CRISPR/Cas13a RNA-editing system for glioma
por: Wu, Ye, et al.
Publicado: (2023)

Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma
por: Kenkel, Troy J., et al.
Publicado: (2023)

Sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma
por: Liu, Ying, et al.
Publicado: (2022)

CRISPR-Cas9 DNA Base-Editing and Prime-Editing
por: Kantor, Ariel, et al.
Publicado: (2020)

Computational Tools and Resources for CRISPR/Cas Genome Editing
por: Li, Chao, et al.
Publicado: (2023)

Commentary: RNA editing with CRISPR-Cas13
por: Matsoukas, Ianis G.
Publicado: (2018)

Genome Editing in Bacteria: CRISPR-Cas and Beyond
por: Arroyo-Olarte, Ruben D., et al.
Publicado: (2021)

CRISPR/Cas9 or prime editing? – It depends on…
por: Schenke, Dirk
Publicado: (2020)

Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγ production
por: Guo, Yelei, et al.
Publicado: (2023)

Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing
por: Wagner, Dimitrios L., et al.
Publicado: (2022)

One-Step Assembly of a PRRSV Infectious cDNA Clone and a Convenient CRISPR/Cas9-Based Gene-Editing Technology for Manipulation of PRRSV Genome
por: Zhang, Hejin, et al.
Publicado: (2023)

Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy
por: Tipanee, Jaitip, et al.
Publicado: (2022)

Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
por: Paillassa, Jérôme, et al.
Publicado: (2021)

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
por: Ababneh, Hazim S., et al.
Publicado: (2023)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

HDAC inhibitors improve CRISPR-Cas9 mediated prime editing and base editing
por: Liu, Nan, et al.
Publicado: (2022)

HDAC inhibitors improve CRISPR-Cas9 mediated prime editing and base editing
por: Liu, Nan, et al.
Publicado: (2022)

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy
por: Li, Chenggong, et al.
Publicado: (2020)

Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies
por: Yan, Xin, et al.
Publicado: (2022)

Methods and applications of CRISPR/Cas system for genome editing in stem cells
por: Yang, Guang, et al.
Publicado: (2019)

CD58 loss in tumor cells confers functional impairment of CAR T cells
por: Yan, Xin, et al.
Publicado: (2022)

CRISPR/Cas: a potential gene-editing tool in the nervous system
por: Gao, Yanxia, et al.
Publicado: (2020)

CRISPR/Cas9-based gene activation and base editing in Populus
por: Yao, Tao, et al.
Publicado: (2023)

Clinical development of CAR T cell therapy in China: 2020 update
por: Wei, Jianshu, et al.
Publicado: (2020)

Inducible in vivo genome editing with CRISPR/Cas9
por: Dow, Lukas E, et al.
Publicado: (2015)

The Rise of CRISPR/Cas for Genome Editing in Stem Cells
por: Shui, Bing, et al.
Publicado: (2016)

Efficient Mitochondrial Genome Editing by CRISPR/Cas9
por: Jo, Areum, et al.
Publicado: (2015)

Multiplex genome editing of microorganisms using CRISPR-Cas
por: Adiego-Pérez, Belén, et al.
Publicado: (2019)

CRISPR/Cas9: Transcending the Reality of Genome Editing
por: Chira, Sergiu, et al.
Publicado: (2017)

Genome Editing in Cotton with the CRISPR/Cas9 System
por: Gao, Wei, et al.
Publicado: (2017)

Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing
por: Wilbie, Danny, et al.
Publicado: (2019)

Applications of the CRISPR/Cas system beyond gene editing
por: Anton, Tobias, et al.
Publicado: (2018)

CRISPR/Cas9 Editing for Gaucher Disease Modelling
por: Pavan, Eleonora, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jrc3cfffn3ohql2d3vv3rcak08